22 results on '"Richard Lomas"'
Search Results
2. P21-A141 Quantification of bioactive factors in human serum eyedrops
- Author
-
Paul Rooney, Akila Chandrasekar, Richard Lomas, Valentina Barrera, and Mark James Eagle
- Subjects
Ophthalmology ,RE1-994 - Published
- 2023
- Full Text
- View/download PDF
3. 2 Impact of COVID-19 on a national serum eyedrops programme in the UK
- Author
-
Richard Lomas and Lauren Roberts
- Subjects
Ophthalmology ,RE1-994 - Published
- 2022
- Full Text
- View/download PDF
4. 28 Validation of a closed system for dispensing serum eye drops
- Author
-
Paul Rooney, Akila Chandrasekar, Richard Lomas, Penny Hogg, Roisin Vere, and Dwynwen Elen
- Subjects
Ophthalmology ,RE1-994 - Published
- 2022
- Full Text
- View/download PDF
5. Study protocol for a multicentre, randomised controlled trial to compare the use of the decellularised dermis allograft in addition to standard care versus standard care alone for the treatment of venous leg ulceration: DAVE trial
- Author
-
John Norrie, Sarrah Peerbux, Nicky Cullum, Akila Chandrasekar, Richard Lomas, Andrew Bradbury, Karen Dhillon, Sarah Onida, Francine Heatley, Layla Bolton, Tristan Lane, David Epstein, Manjit Gohel, Keith Poskitt, Robert J Lee, and A H Davies
- Subjects
Medicine - Abstract
Introduction Venous leg ulceration (VLU), the most common type of chronic ulcer, can be difficult to heal and is a major cause of morbidity and reduced quality of life. Although compression bandaging is the principal treatment, it is time-consuming and bandage application requires specific training. There is evidence that intervention on superficial venous incompetence can help ulcer healing and recurrence, but this is not accessible to all patients. Hence, new treatments are required to address these chronic wounds. One possible adjuvant treatment for VLU is human decellularised dermis (DCD), a type of skin graft derived from skin from deceased tissue donors. Although DCD has the potential to promote ulcer healing, there is a paucity of data for its use in patients with VLU.Methods and analysis This is a multicentre, parallel group, pragmatic randomised controlled trial. One hundred and ninety-six patients with VLU will be randomly assigned to receive either the DCD allograft in addition to standard care or standard care alone. The primary outcome is the proportion of participants with a healed index ulcer at 12 weeks post-randomisation in each treatment arm. Secondary outcomes include the time to index ulcer healing and the proportion of participants with a healed index ulcer at 12 months. Changes in quality of life scores and cost-effectiveness will also be assessed. All analyses will be carried out on an intention-to-treat (ITT) basis. A mixed-effects, logistic regression on the outcome of the proportion of those with the index ulcer healed at 12 weeks will be performed. Secondary outcomes will be assessed using various statistical models appropriate to the distribution and nature of these outcomes.Ethics and dissemination Ethical approval was granted by the Bloomsbury Research Ethics Committee (19/LO/1271). Findings will be published in a peer-reviewed journal and presented at national and international conferences.Trial registration number ISRCTN21541209.
- Published
- 2021
- Full Text
- View/download PDF
6. Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial
- Author
-
Richard Leigh, Elizabeth McGinnis, Peter Vowden, Roberta Longo, James Wason, Sarah Brown, Paul Chadwick, Catherine Fernandez, Linda Sharples, Ian Chetter, Jane Nixon, Myka Ransom, Rachael Gilberts, Frances Game, Chris Bojke, Akila Chandrasekar, Howard Collier, Shervanthi Homer-Vanniasinkam, Edward Jude, Richard Lomas, and David Russell
- Subjects
Medicine - Abstract
Introduction Diabetes affects more than 425 million people worldwide with a lifetime risk of diabetic foot ulcer (DFU) of up to 25%. Management includes wound debridement, wound dressings, offloading, treatment of infection and ischaemia, optimising glycaemic control; use of advanced adjuvant therapies is limited by high cost and lack of robust evidence.Methods and analysis A multicentre, seamless phase II/III, open, parallel group, multi-arm multi-stage randomised controlled trial in patients with a hard-to-heal DFU, with blinded outcome assessment. A maximum of 447 participants will be randomised (245 participants in phase II and 202 participants in phase III). The phase II primary objective will determine the efficacy of treatment strategies including hydrosurgical debridement ± decellularised dermal allograft, or the combination with negative pressure wound therapy, as an adjunct to treatment as usual (TAU), compared with TAU alone, with patients randomised in a 1:1:1:2 allocation. The outcome is achieving at least 50% reduction in index ulcer area at 4 weeks post randomisation.The phase III primary objective will determine whether one treatment strategy, continued from phase II, reduces time to healing of the index ulcer compared with TAU alone, with participants randomised in a 1:1 allocation. Secondary objectives will compare healing status of the index ulcer, infection rate, reulceration, quality of life, cost-effectiveness and incidence of adverse events over 52 weeks post randomisation. Phase II and phase III primary endpoint analysis will be conducted using a mixed-effects logistic regression model and Cox proportional hazards regression, respectively. A within-trial economic evaluation will be undertaken; the primary economic analysis will be a cost-utility analysis presenting ICERs for each treatment strategy in rank order of effectiveness, with effects expressed as quality-adjusted life years.The trial has predefined progression criteria for the selection of one treatment strategy into phase III based on efficacy, safety and costs at 4 weeks.Ethics and dissemination Ethics approval has been granted by the National Research Ethics Service (NRES) Committee Yorkshire and The Humber - Bradford Leeds Research Ethics Committee; approved 26 April 2017; (REC reference: 17/YH/0055). There is planned publication of a monograph in National Institute for Health Research journals and main trial results and associated papers in high-impact peer-reviewed journals.Trial registration number ISRCTN64926597; registered on 6 June 2017
- Published
- 2020
- Full Text
- View/download PDF
7. The Normans in Ireland: Leinster, 1167–1247
- Author
-
Richard Lomas
- Published
- 2022
8. 28 Validation of a closed system for dispensing serum eye drops
- Author
-
Penny Hogg, Roisin Vere, Dwynwen Elen, Richard Lomas, Akila Chandrasekar, and Paul Rooney
- Published
- 2022
- Full Text
- View/download PDF
9. 2 Impact of COVID-19 on a national serum eyedrops programme in the UK
- Author
-
Lauren Roberts and Richard Lomas
- Published
- 2022
- Full Text
- View/download PDF
10. Evaluating risk, safety and efficacy of novel reproductive techniques and therapies through the EuroGTP II risk assessment tool
- Author
-
Esteve Trias, 1, Martine Nijs, 2, 3 4, Ioana Adina Rugescu, Francesco Lombardo, 5, Gueorgui Nikolov, 5, Veerle Provoost, 6, Annelies Tolpe, 7, Nathalie Vermeulen, 8, Zdravka Veleva, 9, Rita Piteira 10, Ricardo Casaroli-Marano 10, Kelly Tilleman, 7, EuroGTP II Study Group:EuroGTP II Study Group: Anna Vilarrodona, A Rita Piteira, Elba, Agustí, Elisabet, Tahull, Esteve, Trias, Eva Maria Martinez, Ivan, Miranda, Jaime, Tabera, Maria Luisa Perez, Marta, Torrabadella, Nausica, Otero, Oscar, Fariñas, Patricia, López-Chicón, Sergi, Querol, Ricardo, Casaroli, Akila, Chandrasekar, Kyle, Bennett, Paul, Rooney, Richard, Lomas, Mar, Carmona, Esteban, Molano, Myriam, Ormeño, Branka Golubić Ćepulić, Ivan, Rozman, Marijana, Dragović, Cristina, Pintus, Eliana, Porta, Fiorenza, Bariani, Letizia, Lombardini, Liliam, Santilli, Mariapia, Mariani, Paola Di Ciaccio, Silvia, Pisanu, Artur, Kamiński, Izabela, Uhrynowska-Tyszkiewicz, Ewa, Olender, Anne Marie van Walraven, Arlinke, Bokhorst, Ingrid van Veen, Kelly, Tilleman, Tolpe, Annelies, Veerle, Provoost, Lieve, Nuytinck, Maryana, Simeonova, Daniela, Staneva-Petkova, Dessislava, Tzoneva, Tsvetelina, Kircheva-Nikolova, Violetta, Marinkova, Valery, Georgiev, Yoran, Peev, Elizabeth, Manova, Cecilia, Surján, Éva, Belicza, Gábor, Szarvas, Judit, Lám, László, Bencze, Martin, Börgel, Mareike, Derks, Sibylla, Schwarz, Ramadan, Jashari, Richard, N Noumanje, Rosario Daiz Rodriguez, Tiia, Tallinen, Hanna, Kankkonen, Toni-Karri, Pakarinen, Gilbert, Verbeken, Jean-Paul, Pirnay, Thomas, Rose, Jean-Pierre, Draye, Simone, Hennerbichler, Jill, Davies, Jacinto, Ibañez, Cristina, Magli, Nathalie, Vermeulen, Monserrat, Boada, Eoin, Mcgrath, John, Armitage, Gary, Jones, Marta, Fraga, Dulce, Roldao, Josefina, Oliveira, Adolfo, Paolin, Diletta, Trojan, Giulia, Montagner, Diego, Ponzin, Stefano, Ferrari, Lombardo, Francesco, Carlijn, Voermans, Nelleke, Richters, Ioana Adina Rugescu, Gianpaolo, Azzena, Fabozzo, Assunta, Helene, Schoenmans, Jose Luis Pomar, Pablo, Gelber, Katalin, Rajczy, Boris, Calmels, Stephan, Mielke, Tanja, Netelenbos, Mirko, Ragazzo, Gueorgui, Nikolov, Marton, Elisabetta, Martine, Nijs, Antonella, Franch, Gianluca, Piovan, Francesco, Dell'Antonia, Martyn, Snow, Ines, Bojanic, Zdravka, Veleva, Grezgorz, Basak, Margarida, Amil, Sandra, Shaw, Aurora, Navarro, Tim, Spalding, and Peter, Verdonk
- Subjects
safety ,Research Report ,Risk analysis ,Quality management ,Reproductive Techniques, Assisted ,risk analysis ,Computer science ,media_common.quotation_subject ,efficacy ,gamete ,embryo ,030209 endocrinology & metabolism ,Context (language use) ,Risk management tools ,Risk Assessment ,03 medical and health sciences ,0302 clinical medicine ,Quality (business) ,Prospective Studies ,Duration (project management) ,Risk management ,media_common ,novel techniques ,validation ,030219 obstetrics & reproductive medicine ,business.industry ,assisted reproduction technologies ,Rehabilitation ,reproductive tissue ,Obstetrics and Gynecology ,Germ Cells ,Reproductive Medicine ,Risk analysis (engineering) ,business ,Risk assessment ,quality management - Abstract
STUDY QUESTIONCan risks associated with novelties in assisted reproduction technologies (ARTs) be assessed in a systematic and structured way?SUMMARY ANSWERAn ART-specific risk assessment tool has been developed to assess the risks associated with the development of novelties in ART (EuroGTP II-ART).WHAT IS KNOWN ALREADYHow to implement new technologies in ART is well-described in the literature. The successive steps should include testing in animal models, executing pre-clinical studies using supernumerary gametes or embryos, prospective clinical trials and finally, short- and long-term follow-up studies on the health of the offspring. A framework categorizing treatments from experimental through innovative to established according to the extent of the studies conducted has been devised. However, a systematic and standardized methodology to facilitate risk evaluation before innovations are performed in a clinical setting is lacking.STUDY DESIGN, SIZE, DURATIONThe EuroGTP II-ART risk assessment tool was developed on the basis of a generic risk assessment algorithm developed for tissue and cell therapies and products (TCTPs) in the context of the project ‘Good Practices for demonstrating safety and quality through recipient follow-up European Good Tissue and cells Practices II (EuroGTP II)’. For this purpose, a series of four meetings was held in which eight ART experts participated. In addition, several tests and simulations were undertaken to fine-tune the final tool.PARTICIPANTS/MATERIALS, SETTING, METHODSThe three steps comprising the EuroGTP II methodology were evaluated against its usefulness and applicability in ART. Ways to improve and adapt the methodology into ART risk assessment were agreed and implemented.MAIN RESULTS AND THE ROLE OF CHANCEAssessment of the novelty (Step 1), consisting of seven questions, is the same as for other TCTPs. Practical examples were included for better understanding. Identification of potential risks and consequences (Step 2), consisting of a series of risks and risk consequences to consider during risk assessment, was adapted from the generic methodology, adding more potential risks for processes involving gonadic tissues. The algorithm to score risks was also adapted, giving a specific range of highest possible risk scores. A list of strategies for risk reduction and definition of extended studies required to ensure effectiveness and safety (Step 3) was also produced by the ART experts, based on generic EuroGTP II methodology. Several explanations and examples were provided for each of the steps for better understanding within this field.LIMITATIONS, REASONS FOR CAUTIONA multidisciplinary team is needed to perform risk assessment, to interpret results and to determine risk mitigation strategies and/or next steps required to ensure the safety in the clinical use of novelties.WIDER IMPLICATIONS OF THE FINDINGSThis is a dynamic tool whose value goes beyond assessment of risk before implementing a novel ART in clinical practice, to re-evaluate risks based on information collected during the process.STUDY FUNDING / COMPETING INTEREST(S)This study was called EUROGTP II and was funded by the European Commission (Grant agreement number 709567). The authors declare no competing interests concerning the results of this study.
- Published
- 2020
- Full Text
- View/download PDF
11. EuroGTP II: a tool to assess risk, safety and efficacy of substances of human origin
- Author
-
Esteve, Trias, Richard, Lomas, Jaime, Tabera, RITA PITEIRA, A., Kelly, Tilleman, CASAROLI-MARANO, RICARDO P., and AKILA CHANDRASEKAR, ON BEHALF OF EUROGTP II STUDY GROUP, and Marton, Elisabetta
- Subjects
030219 obstetrics & reproductive medicine ,Computer science ,Process (engineering) ,Health Policy ,Cell- and Tissue-Based Therapy ,Public Health, Environmental and Occupational Health ,Risk-based testing ,Novelty ,General Medicine ,Risk Assessment ,Translational Research, Biomedical ,03 medical and health sciences ,Treatment Outcome ,0302 clinical medicine ,Risk analysis (engineering) ,Risk Factors ,Humans ,Clinical safety ,European Union ,030212 general & internal medicine ,Clinical efficacy ,Product (category theory) ,Risk assessment - Abstract
A systematic methodology, able to assess risk and predict clinical safety and efficacy of Substances of Human Origin’ (SoHO) has been developed. The model consists of a risk based approach taking into account factors such as novelty of the product, preparation process, clinical indication, and its technical complexity.
- Published
- 2019
- Full Text
- View/download PDF
12. Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial
- Author
-
Chris Bojke, Roberta Longo, Howard Collier, David Russell, Peter Vowden, Jane Nixon, Rachael Gilberts, Richard Lomas, Shervanthi Homer-Vanniasinkam, Ian Chetter, Sarah Brown, Nikki Dewhirst, Myka Ransom, Paul Chadwick, Catherine Fernandez, Frances L. Game, Edward B. Jude, Akila Chandrasekar, James Wason, Richard Leigh, Elizabeth McGinnis, Linda D. Sharples, Brown, Sarah [0000-0002-1840-3786], and Apollo - University of Cambridge Repository
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Cost-Benefit Analysis ,statistics & research methods ,diabetes & endocrinology ,law.invention ,Clinical Trials, Phase II as Topic ,Randomized controlled trial ,Quality of life ,law ,Internal medicine ,Negative-pressure wound therapy ,medicine ,Clinical endpoint ,Diabetes Mellitus ,Humans ,Multicenter Studies as Topic ,Acellular Dermis ,wound management ,Adverse effect ,Randomized Controlled Trials as Topic ,clinical trials ,Wound Healing ,business.industry ,General Medicine ,Skin Transplantation ,medicine.disease ,Diabetic foot ,Diabetic Foot ,Clinical trial ,Diabetes and Endocrinology ,Diabetic foot ulcer ,Clinical Trials, Phase III as Topic ,Debridement ,Quality of Life ,Quality-Adjusted Life Years ,business ,Negative-Pressure Wound Therapy - Abstract
IntroductionDiabetes affects more than 425 million people worldwide with a lifetime risk of diabetic foot ulcer (DFU) of up to 25%. Management includes wound debridement, wound dressings, offloading, treatment of infection and ischaemia, optimising glycaemic control; use of advanced adjuvant therapies is limited by high cost and lack of robust evidence.Methods and analysisA multicentre, seamless phase II/III, open, parallel group, multi-arm multi-stage randomised controlled trial in patients with a hard-to-heal DFU, with blinded outcome assessment. A maximum of 447 participants will be randomised (245 participants in phase II and 202 participants in phase III). The phase II primary objective will determine the efficacy of treatment strategies including hydrosurgical debridement ± decellularised dermal allograft, or the combination with negative pressure wound therapy, as an adjunct to treatment as usual (TAU), compared with TAU alone, with patients randomised in a 1:1:1:2 allocation. The outcome is achieving at least 50% reduction in index ulcer area at 4 weeks post randomisation.The phase III primary objective will determine whether one treatment strategy, continued from phase II, reduces time to healing of the index ulcer compared with TAU alone, with participants randomised in a 1:1 allocation. Secondary objectives will compare healing status of the index ulcer, infection rate, reulceration, quality of life, cost-effectiveness and incidence of adverse events over 52 weeks post randomisation. Phase II and phase III primary endpoint analysis will be conducted using a mixed-effects logistic regression model and Cox proportional hazards regression, respectively. A within-trial economic evaluation will be undertaken; the primary economic analysis will be a cost-utility analysis presenting ICERs for each treatment strategy in rank order of effectiveness, with effects expressed as quality-adjusted life years.The trial has predefined progression criteria for the selection of one treatment strategy into phase III based on efficacy, safety and costs at 4 weeks.Ethics and disseminationEthics approval has been granted by the National Research Ethics Service (NRES) Committee Yorkshire and The Humber - Bradford Leeds Research Ethics Committee; approved 26 April 2017; (REC reference: 17/YH/0055). There is planned publication of a monograph in National Institute for Health Research journals and main trial results and associated papers in high-impact peer-reviewed journals.Trial registration numberISRCTN64926597; registered on 6 June 2017
- Published
- 2020
13. The Normans in Ireland : Leinster, 1167–1247
- Author
-
Richard A. Lomas, Richard Lomas, Richard A. Lomas, and Richard Lomas
- Subjects
- History, Normans--History--To 1500.--Ireland, Normans
- Abstract
The Norman invasion of Britain, as depicted in the Bayeux Tapestry, is well known, but the later invasion of Ireland is much less well documented. Yet much of what we see today in Irish heritage has Norman roots. Ireland and Britain have many similarities, although relations between them have too often descended into bitterness and violence. This book goes back to the starting point of this, more than eight hundred years ago. Beginning with Irish history before the Norman invasion, the book describes how Ireland was conquered and settled by the French-speaking Normans from north-west France, whose language and culture had already come to dominate most of Britain.It looks at the creation and government of a large region called the Liberty of Leinster between 1167 and 1247, a turning point in Irish history, identifying the Frankish institutions imposed upon Ireland by its Anglo-Norman conquerors. The Normans were not always belligerent conquerors, but they were innovators and reformers, who incorporated the sensible traditions and practices of their subjugated lands into their new government. In little over one hundred years the Normans had a transforming effect on British and Irish societies and, while different in many ways, both countries benefited from their legacy.
- Published
- 2021
14. Assessment of the permeability properties of cryopreservation outer bags used in NHSBT
- Author
-
P. Hogg, Paul Rooney, John N. Kearney, and Richard Lomas
- Subjects
Materials science ,Trace Amounts ,Hydrogen ,040301 veterinary sciences ,Biomedical Engineering ,chemistry.chemical_element ,Permeability ,Cryopreservation ,0403 veterinary science ,Biomaterials ,03 medical and health sciences ,0302 clinical medicine ,TRACER ,Product Packaging ,Humans ,Coloring Agents ,Drug Packaging ,Transplantation ,030219 obstetrics & reproductive medicine ,Chromatography ,Temperature ,Equipment Design ,04 agricultural and veterinary sciences ,Cell Biology ,Permeation ,Contamination ,Liquid nitrogen ,Permeability (earth sciences) ,chemistry ,Blood Preservation ,Blood Banks - Abstract
This study was carried out to investigate leakage/transport across the bag material of six outer cryopreservation bags in common use within NHS Blood and Transplant. In order to do this two different leak testing procedures; coloured dye and hydrogen tracer gas, were used. The data obtained show that a coloured dye cannot permeate through the materials both at room temperature and following storage at liquid nitrogen temperature (- 196 °C). In addition, when filled with the smallest elemental molecule, hydrogen, in the form of a tracer gas, all of the bags only allowed trace amounts of hydrogen to escape, either through the seal or the bag material. The data indicated that each of the bag materials tested would be capable of preventing bacterial or viral cross-contamination as long as the material remained intact.
- Published
- 2018
- Full Text
- View/download PDF
15. The Principles of Process Validation and Equipment Qualification
- Author
-
Richard Lomas and Martell Winters
- Subjects
Engineering ,business.industry ,Tissue bank ,Equipment Qualification ,Process validation ,business ,Manufacturing engineering - Published
- 2012
- Full Text
- View/download PDF
16. Development of a bacteriophage model system to investigate virus inactivation methods used in the treatment of bone allografts
- Author
-
Gillian Scott, Anthony Jones, Carol Bienek, Richard Lomas, George Galea, Lynsay MacKay, and J.N. Kearney
- Subjects
Ethylene Oxide ,medicine.medical_specialty ,Virus inactivation ,Bone stock ,Biomedical Engineering ,Model system ,Buffers ,Models, Biological ,Bone and Bones ,Biomaterials ,Bacteriophage ,Bioburden ,Humans ,Transplantation, Homologous ,Medicine ,Bacteriophages ,Transplantation ,Bone Transplantation ,biology ,business.industry ,Reproducibility of Results ,Sterilization ,Cell Biology ,Sterilization (microbiology) ,biology.organism_classification ,Surgery ,Freeze Drying ,Gamma Rays ,Virus Inactivation ,business ,Disease transmission ,Biomedical engineering ,Gamma irradiation - Abstract
Bone allografts are commonly used in a variety of surgical procedures, to reconstruct lost bone stock and to provide mechanical support during the healing process. Due to concerns regarding the possibility of disease transmission from donor to recipient, and of contamination of grafts during retrieval and processing procedures, it is common practice to sterilise bone allografts prior to issue for clinical use. It is vital that the sterilisation processes applied to allografts are validated to demonstrate that they achieve the required level of bioburden reduction, and by extension that validated models are used for these studies. Two common sterilisation protocols applied to bone allografts are gamma irradiation and ethylene oxide gas sterilisation, and there are currently no validated models available for measuring the anti-viral efficacy of ethylene oxide treatment with regard to bone allografts or readily useable models for assessing the anti-viral efficiency of gamma irradiation treatment. We have developed and validated models for both these sterilisation processes, using the bacteriophage varphix174, and utilised the models to measure the antiviral activity of the standard ethylene oxide and gamma irradiation sterilisation processes applied to bone allografts by the National Blood Service. For the irradiation model, we also utilised bacterial spores (Bacillus pumilus). Our results show that ethylene oxide sterilisation (which can only be applied to lyophilised grafts) inactivated6.1 log(10) of the model virus, and gamma irradiation (at 25 -40 kGy and applied to frozen allografts) inactivated 3.6 - 4.0 log(10) of the model virus and4 log(10) of the bacterial spores. Gamma irradiation at this dosage is therefore not in itself a sterilisation process with respect to viruses.
- Published
- 2006
- Full Text
- View/download PDF
17. St Cuthbert and the Border, c.1080–c.1300
- Author
-
Richard Lomas
- Published
- 2005
- Full Text
- View/download PDF
18. The Impact of Border Warfare: The Scots and South Tweedside, c. 1290-c.1520
- Author
-
Richard Lomas
- Subjects
History ,language ,Forestry ,Scots ,Pulp and paper industry ,language.human_language - Published
- 1996
- Full Text
- View/download PDF
19. The effect of amniotic membrane preparation method on its ability to serve as a substrate for the ex-vivo expansion of limbal epithelial cells
- Author
-
John N. Kearney, Genevieve A. Secker, Richard Lomas, Stephen J. Tuft, Julie T. Daniels, Alex J. Shortt, Stacy P. Wilshaw, Shortt, Alex J, Secker, Genevieve A, Lomas, Richard J, Wilshaw, Stacy P, Kearney, John N, Tuft, Stephen J, and Daniels, Julie T
- Subjects
Glycerol ,Time Factors ,Cryoprotectant ,somatic stem cell biology ,Ham test ,Population ,Biophysics ,Bioengineering ,Balanced salt solution ,Cell Count ,Biology ,Limbus Corneae ,Cell morphology ,Cryopreservation ,Biomaterials ,Andrology ,cornea ,Materials Testing ,ATP Binding Cassette Transporter, Subfamily G, Member 2 ,Humans ,Amnion ,education ,Cell Shape ,Cell Proliferation ,education.field_of_study ,amniotic membrane ,limbus ,Tumor Suppressor Proteins ,food and beverages ,Epithelial Cells ,Anti-Bacterial Agents ,Neoplasm Proteins ,stem cell ,niche ,Mechanics of Materials ,Amniotic epithelial cells ,Immunology ,Ceramics and Composites ,Trans-Activators ,ATP-Binding Cassette Transporters ,sense organs ,Stem cell ,Transcription Factors - Abstract
Human amniotic membrane (HAM) is employed as a substrate for the ex-vivo expansion of limbal epithelial cells (LECs) used to treat corneal epithelial stem cell deficiency in humans. The optimal method of HAM preparation for this purpose is unknown. This study evaluated the ability of different preparations of stored HAM to serve as substrates for LEC expansion ex-vivo. The effect of removing the amniotic epithelial cells (decellularisation) from HAM prior to seeding of LECs, the effect of glycerol cryopreservation and the effect of peracetic acid (PAA) sterilization and antibiotic disinfection were evaluated using different HAM test groups. Human LECs were cultured on each preparation and the following outcomes were assessed: confluence of growth, cell density, cell morphology and expression of the putative LESC markers deltaN-p63alpha and ABCG2. Removing amniotic epithelial cells prior to seeding of LECs resulted in a higher percentage of confluence but a lower cell density than intact HAM suggesting that decellularisation does not increase proliferation, but rather that it facilitates migration of LECs resulting in larger cells. Decellularisation did not affect the percentage of cells expressing the putative LESC markers deltaN-p63alpha (
- Published
- 2009
20. THE OSTEOINDUCTIVE PROPERTIES OF DEMINERALISED BONE MATRIX GRAFTS
- Author
-
Richard Lomas and John N. Kearney
- Subjects
business.industry ,Medicine ,Bone matrix ,business ,Biomedical engineering - Published
- 2004
- Full Text
- View/download PDF
21. Radiofrequency-generated glow discharge treatment: potential benefits for polyester ligaments
- Author
-
John N. Kearney, Toshiyuki Kikuchi, Satoshi Tsukazaki, Bahaa B. Seedhom, Edward J. Wood, John Richard James Rowland, Kyosuke Fujikawa, and Richard Lomas
- Subjects
medicine.medical_specialty ,Materials science ,chemistry.chemical_compound ,Tensile Strength ,Ultimate tensile strength ,Materials Testing ,Polyethylene terephthalate ,medicine ,Humans ,Orthopedics and Sports Medicine ,Glow discharge ,Polyethylene Terephthalates ,Biomaterial ,Prostheses and Implants ,Fibroblasts ,Radiofrequency Therapy ,Surgery ,Biomechanical Phenomena ,Culture Media ,Residual strength ,Polyester ,medicine.anatomical_structure ,chemistry ,Ligament ,Wettability ,Synovial membrane ,Biomedical engineering - Abstract
This multicenter study has revealed that treating a woven polyethylene terephthalate (polyester) ligament with a radiofrequency (RF)-generated glow discharge (RFGD) produces marked benefits in terms of increased cell attachment and proliferation on the implant surface. In vitro tests of the same material revealed that the number of synovial fibroblasts attached to the treated samples after 14 days was four times that of the untreated material. Many of the cells were spread over the surface of a single filament, and some formed bridges between one filament and the next. The incorporation of [(3)H]-thymidine by synovial stromal cells (a measure of the amount of cell division) growing on the treated material was five times that on the untreated samples. The amount of DNA present on the treated material was also found to be almost an order of magnitude greater than that on untreated samples. This increase in cell attachment and proliferation is almost certainly related to a notable increase in wettability of the polyester surface induced by treatment. Mechanical tests revealed that, for ligaments with a nominal ultimate tensile strength of 2100 N, RF-generated glow treatment reduced the ligament's strength by 12% but increased its stiffness by 15%. After a medium-term fatigue test (10.8 million cycles), however, there appeared to be recovery of the mechanical properties, with the strength and stiffness of untreated and treated samples being essentially the same. After exhaustive fatigue tests (more than 62 million cycles) the residual strength of the treated ligaments was only 9% lower than that of the unfatigued and untreated ligaments.
- Published
- 2003
22. The black death in county Durham
- Author
-
Richard Lomas
- Subjects
History ,education.field_of_study ,Population ,Outbreak ,Special Interest Group ,Plague (disease) ,Circumstantial evidence ,education ,Genealogy - Abstract
The purpose of this article is twofold. First, it attempts to estimate the number of deaths in percentage terms which County Durham may have experienced in 1349 during the first outbreak of the plague and to compare this with what happened in other parts of England. Following this is a consideration of the length of time over which the plague continued to have an adverse effect on the level of population and when a recovery began. All the evidence relates to properties belonging to the cathedral priory of Durham and is largely of an economic nature and therefore indirect and circumstantial. The exceptions are five short parchment rolls on which the monks recorded the names of their tenants who died in 1349, and it is the existence of this direct evidence that has made this study of special interest.
- Published
- 1989
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.